Clinical Trial

Edgewise Therapeutics to Host Webcast Event to Discuss Top-Line Results from Phase 2 CIRRUS-HCM 28-Day Trial of EDG-7500 in Hypertrophic Cardiomyopathy (HCM) on Wednesday, April 2 at 8:30 am Eastern TimeEdgewise Therapeutics to Host Webcast Event to Discuss Top-Line Results from Phase 2 CIRRUS-HCM 28-Day Trial of EDG-7500 in Hypertrophic Cardiomyopathy (HCM) on Wednesday, April 2 at 8:30 am Eastern Time

Edgewise Therapeutics to Host Webcast Event to Discuss Top-Line Results from Phase 2 CIRRUS-HCM 28-Day Trial of EDG-7500 in Hypertrophic Cardiomyopathy (HCM) on Wednesday, April 2 at 8:30 am Eastern Time

BOULDER, Colo., March 26, 2025 /PRNewswire/ -- Edgewise Therapeutics, Inc., (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company, today announced…

3 hours ago
Medrio Enhances RTSM For Faster Clinical Trial Starts and Greater FlexibilityMedrio Enhances RTSM For Faster Clinical Trial Starts and Greater Flexibility

Medrio Enhances RTSM For Faster Clinical Trial Starts and Greater Flexibility

SAN FRANCISCO, March 26, 2025 /PRNewswire/ -- Medrio, a global leader in clinical trial technology, today announced enhancements to its randomization…

9 hours ago
Rarecells Inc. Appoints Dr. Neil Kurtz to Board of DirectorsRarecells Inc. Appoints Dr. Neil Kurtz to Board of Directors

Rarecells Inc. Appoints Dr. Neil Kurtz to Board of Directors

NEW YORK and PARIS, March 26, 2025 /PRNewswire/ -- Rarecells Inc., a pioneering company in liquid biopsy technology, is pleased…

9 hours ago
DATAcc by DiMe Releases Resources to Build the Business Case for Digital EndpointsDATAcc by DiMe Releases Resources to Build the Business Case for Digital Endpoints

DATAcc by DiMe Releases Resources to Build the Business Case for Digital Endpoints

New tools will calculate the ROI of using digital endpoints in clinical trials, empowering greater innovation in research BOSTON, March…

9 hours ago
Silo Pharma Achieves Key Milestone with First Dosing in IND-Enabling GLP Study for SPC-15 as a Groundbreaking PTSD TreatmentSilo Pharma Achieves Key Milestone with First Dosing in IND-Enabling GLP Study for SPC-15 as a Groundbreaking PTSD Treatment

Silo Pharma Achieves Key Milestone with First Dosing in IND-Enabling GLP Study for SPC-15 as a Groundbreaking PTSD Treatment

Preclinical Data to Support Advancement Toward First-in-Human Clinical Trials SARASOTA, FL, March 26, 2025 (GLOBE NEWSWIRE) -- Silo Pharma, Inc.…

12 hours ago
Bluejay Therapeutics Announces First Patient Dosed in AZURE-1 Global Pivotal Clinical Trial Evaluating Brelovitug (BJT-778) as a Monotherapy Treatment for Chronic Hepatitis DBluejay Therapeutics Announces First Patient Dosed in AZURE-1 Global Pivotal Clinical Trial Evaluating Brelovitug (BJT-778) as a Monotherapy Treatment for Chronic Hepatitis D

Bluejay Therapeutics Announces First Patient Dosed in AZURE-1 Global Pivotal Clinical Trial Evaluating Brelovitug (BJT-778) as a Monotherapy Treatment for Chronic Hepatitis D

AZURE-1 will evaluate the efficacy and safety of brelovitug compared to delayed treatmentREDWOOD CITY, Calif., March 26, 2025 (GLOBE NEWSWIRE)…

12 hours ago
BriaCell to Present Clinical and Preclinical Data at the 2025 AACR ConferenceBriaCell to Present Clinical and Preclinical Data at the 2025 AACR Conference

BriaCell to Present Clinical and Preclinical Data at the 2025 AACR Conference

PHILADELPHIA and VANCOUVER, British Columbia, March 26, 2025 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell”…

12 hours ago
Aligos Therapeutics Presents Positive Data at APASL 2025Aligos Therapeutics Presents Positive Data at APASL 2025

Aligos Therapeutics Presents Positive Data at APASL 2025

SOUTH SAN FRANCISCO, Calif., March 26, 2025 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS, “Aligos”), a clinical stage biopharmaceutical…

12 hours ago
Starton Therapeutics to Present Poster at the American Association for Cancer Research (AACR) Annual Meeting 2025Starton Therapeutics to Present Poster at the American Association for Cancer Research (AACR) Annual Meeting 2025

Starton Therapeutics to Present Poster at the American Association for Cancer Research (AACR) Annual Meeting 2025

PARAMUS, N.J., March 26, 2025 (GLOBE NEWSWIRE) -- Starton Therapeutics Inc. (“Starton” or the “Company”), a clinical-stage biotechnology company transforming…

12 hours ago
Nuvectis Pharma Announces Upcoming Presentations for NXP900 at the 2025 American Association for Cancer Research MeetingNuvectis Pharma Announces Upcoming Presentations for NXP900 at the 2025 American Association for Cancer Research Meeting

Nuvectis Pharma Announces Upcoming Presentations for NXP900 at the 2025 American Association for Cancer Research Meeting

Fort Lee, NJ, March 26, 2025 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQ: NVCT) ("Nuvectis" or the "Company"), a clinical-stage…

12 hours ago